<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770159</url>
  </required_header>
  <id_info>
    <org_study_id>0822-005</org_study_id>
    <secondary_id>MK0822-005</secondary_id>
    <secondary_id>2008_559</secondary_id>
    <nct_id>NCT00770159</nct_id>
  </id_info>
  <brief_title>A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Once-Weekly, Multiple-Dose Study to Investigate the Safety, Tolerability, Plasma Concentration Profile and Effects on Biochemical Markers of Bone Resorption of MK0822 in Healthy Postmenopausal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, PK, and PD of a once weekly dose of MK0822
      in healthy postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Adverse Events</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to Adverse Events</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Time Curve From 0 to 24 Hours (AUC 0-24hr) at Week 1 and Week 3</measure>
    <time_frame>Up to 24 hours postdose, Week 1 and Week 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0822</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to MK0822</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>odanacatib</intervention_name>
    <description>Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo to MK0822</intervention_name>
    <description>Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is less than or equal to 75 years of age

          -  Subject is a postmenopausal female

          -  Subject is within 30% of ideal body weight

          -  Subject is judged to be in good health

          -  Subject is a nonsmoker

          -  Subject is willing to avoid excessive alcohol consumption for the duration of the
             study

          -  Subject is willing to avoid strenuous physical activity for the duration of the study

          -  Subject agrees to refrain from consuming grapefruit or grapefruit juice for the
             duration of the study

        Exclusion Criteria:

          -  Subject has a history of multiple/severe allergies to foods or drugs

          -  Subject has had surgery within 12 weeks of starting study or has given blood within 4
             weeks of starting study

          -  Subject has a history of major GI abnormalities/ulcers, or genitourinary,
             cardiovascular, hepatic, pulmonary, psychiatric, endocrine, or metabolic diseases

          -  Subject has a history of bone disease or treatment with bisphosphonates

          -  Subject has an infection/condition that would suppress the immune system, including
             HIV

          -  Subject has a history of chronic/active hepatic (liver) disease, including Hepatitis B
             and C

          -  Subject regularly uses illegal drugs

          -  Subject consumes more than 3 alcoholic beverages per day

          -  Subject consumes more than 4 cups of brewed coffee (or equivalent caffeinated
             beverages) per day

          -  Subject requires use of any prescription or non-prescription medications during the
             study

          -  Part I only: subject has received treatment with any of the following: any estrogen
             preparation, anabolic steroids, calcitonin, or progestins within 6 months of study
             start; thyroid hormone if not on a stable dose; fluoride treatment greater than
             1mg/day for more than 2 weeks; Glucocorticoid treatment; Vitamin A greater than 10,000
             U/day, vitamin D greater than 2000 U/day, anticonvulsants; selective estrogen receptor
             modulators within 6 months of study start; parathyroid hormone within 2 years of study
             start; or bisphosphonates.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther. 2009 Aug;86(2):175-82. doi: 10.1038/clpt.2009.60. Epub 2009 May 6.</citation>
    <PMID>19421185</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

